Legend Biotech’s Earnings Call Highlights CARVYKTI Surge

Legend Biotech Corporation ((LEGN)) has held its Q1 earnings call. Read on for the main highlights of the call.

Legend Biotech’s latest earnings call struck a notably upbeat tone, underscored by powerful CARVYKTI sales growth, tighter operations, and a clearer path to profitability in 2026. Management acknowledged short‑term pressure on gross margins and lingering clinical and competitive uncertainties, but overall framed these as growing pains on an otherwise constructive growth trajectory.

CARVYKTI Sales Momentum Fuels Top-Line Growth

CARVYKTI net trade sales reached about $597 million in Q1 2026, up 52% year over year and 8% sequentially versus Q4 2025. Growth was broad-based, with the U.S. rising 36% and ex-U.S. markets more than tripling, signaling strong adoption across regions.

Manufacturing Metrics Underscore Operational Strength

Legend highlighted a 99% manufacturing success rate for CARVYKTI, with a median turnaround time of roughly 29 days. More than 95% of orders were released on time, reinforcing confidence in supply reliability as demand scales.

Shift Toward Earlier-Line Use Accelerates

In the U.S., patients in second and third line settings represented 41% of CARVYKTI apheresis volume in Q1, up from 29% a year earlier. This shift signals growing comfort among community physicians and payers in using the therapy earlier in the treatment journey.

Global Commercial Footprint Continues to Expand

CARVYKTI is now available in 18 global markets and at more than 300 treatment sites, underscoring the breadth of the rollout. In the U.S., 148 centers are authorized to deliver the product, with about one-third located in community settings, broadening patient access.

Path to Profitability Comes Into Sharper Focus

Management reiterated expectations for company-wide adjusted profitability in 2026, pointing to visible operating leverage. The Q1 2026 adjusted net loss narrowed to $11 million, or $0.03 per diluted share, from a $27 million loss, or $0.07, in the prior-year quarter.

Balance Sheet Strength Supports Investment Plans

Legend ended the quarter with roughly $835 million in cash, cash equivalents and time deposits, and no long-term debt. This financial cushion gives the company room to fund pipeline development and manufacturing expansion without near-term balance sheet strain.

Pipeline Advances Highlight In Vivo and Next-Gen Assets

The company is pushing multiple In Vivo and next-generation programs forward, including BCMA In Vivo for autoimmune disease and GPRC5D In Vivo for multiple myeloma, both in Phase I. LB2501, a CD19/CD20 In Vivo candidate for NHL, is also in Phase I with initial clinical data planned for a major midyear meeting and 1–2 U.S. IND filings targeted for 2026.

Collaboration Revenue Adds Scale to the P&L

Collaboration revenue, largely from the CARVYKTI partnership with Johnson & Johnson, totaled approximately $298 million in Q1. This contributed to overall revenue of $305 million, helping fund R&D and commercialization while CARVYKTI volumes ramp.

Gross Margin Hit by One-Time Ramp Costs

Gross margin on net product sales dropped to 41% in Q1 from 57% in Q4 2025, a 16-point decline tied mainly to one-time costs from scaling the Raritan and Tech Lane manufacturing sites. Management expects gross margin to recover to above 50% in Q2 as these facilities ramp and efficiencies emerge.

Adjusted Loss Persists Amid GAAP Complexity

Despite progress, the company still posted an adjusted net loss of $11 million in Q1 2026, underscoring that full profitability is not yet achieved. Management also pointed to GAAP versus non-IFRS adjustments, including share-based compensation, depreciation, amortization and FX, which widen the gap between reported and adjusted results.

Accounting for Collaboration Clouds Top-Line Optics

There is a notable discrepancy between CARVYKTI net trade sales of $597 million and Legend’s total recognized revenue of $305 million. Management attributed this to collaboration accounting, which can make it harder for investors to directly compare product sales momentum with reported revenue.

Event-Driven Trials Create Timing Uncertainty

Pivotal CARTITUDE-5 and CARTITUDE-6 trials, key to potential label expansions, are fully enrolled but event-driven, leaving readout timing uncertain. Management suggested those data could emerge in 2026 or 2027, introducing timing risk for future growth inflection points.

In Vivo Programs Still Carry Early-Stage Risk

Legend’s In Vivo programs are in Phase I with limited mature clinical information, and the company has not yet shared detailed safety or efficacy data. That leaves meaningful execution and clinical risk until results are publicly presented, even as expectations for the platform build.

Limited Detail on One-Off Costs Frustrates Visibility

The company declined to quantify the specific one-time impact of the Raritan and Tech Lane ramp on Q1 gross margin. This lack of granularity may complicate near-term modeling for investors trying to separate structural margin levels from temporary cost spikes.

Competitive Landscape Remains Dynamic and Unsettled

Management acknowledged external pressures, including bispecific competitors such as TECVAYLI and partner decisions to discontinue some ex vivo CAR-T programs. Still, Legend argued that the multiple myeloma market is large enough to support different modalities and that CARVYKTI remains well positioned.

Guidance Signals Revenue Growth and Margin Recovery

Looking ahead, Legend guided to company-wide adjusted profitability in 2026, underpinned by continued sequential revenue growth through the year. The company expects gross margin to rebound above 50% in Q2 and to keep improving, while it advances In Vivo programs, targets 1–2 U.S. IND filings in 2026, and awaits event-driven CARTITUDE-5 and -6 readouts in 2026–2027.

Legend’s earnings call painted a picture of a company transitioning from high-growth specialty player toward a more profitable, scaled biopharma business. Strong CARVYKTI demand, tightening operations and a robust balance sheet outweigh near-term margin noise and clinical timing risks, leaving a cautiously optimistic setup for investors tracking the story.